Blood Cancer

A collaborative team of cancer experts from leading academic institutions and organizations has released recommendations for optimal protection against COVID-19 among individuals with blood cancer.

The FDA halted a phase 3 study that was evaluating an investigational gene therapy for a rare neurological disease in young children.

Convalescent plasma treatment appeared associated with a reduction in 30-day mortality among patients with hematologic malignancies hospitalized for COVID-19, according to study results published in JAMA Oncology.

Nearly one-third of people diagnosed with blood cancers indicated they either are unlikely to get a COVID-19 vaccine or are unsure about doing so, survey results released today by Leukemia & Lymphoma Society showed.

Adults with Erdheim-Chester disease, a rare blood cancer, are more likely than those without the disease to have central or primary hypothyroidism and should be screened with a full thyroid panel, according to study findings.

Three organizations awarded grants totaling $6.75 million to fund research into blood cancers.

Dana-Farber Cancer Institute announced the launch of a randomized clinical trial evaluating the use of ibrutinib — an oral medication used to treat blood cancer — in patients with COVID-19.

ASH and ASCO launched data registries to capture important insights and guide patient care during and beyond the COVID-19 pandemic.

ASH Research Collaborative’s Data Hub launched an international data registry to help inform care for individuals with blood cancers and COVID-19.

Patients with cancer often feel overwhelmed by the reality of their disease and may struggle simply to maintain the course of treatment set forth by their oncologist. The additional effort required to seek out appropriate clinical trials, determine their eligibility and travel to trial sites may be more than their limited schedules, finances and emotional reserves permit.